| Observational | Non-decontamination | Topical anti-septica | Antibiotic basedb | Single anti-fungalc |
---|---|---|---|---|---|
Study characteristics | |||||
Listing | Additional file 1: Table S1 | Additional file 1: Table S2 | Additional file 1: Table S3 | Additional file 1: Table S4 | Additional file 1: Table S5 |
Number of studiesd | 142 | 44 | 18 | 61 | 13 |
MV for > 48 h for < 90%e | 41 | 0 | 9 | 16 | 6 |
PPAP for control groups | 0 | 0 | 0 | 10 | 0 |
Trauma ICUsf | 25 | 8 | 3 | 13 | 1 |
CRF as selection criteriag | 11 | 0 | 0 | 11 | 6 |
Paediatric ICU | Â | Â | 1 | 1 | Â |
North American ICU | 36 | 10 | 8 | 6 | 3 |
Study publication year (range) | 1987–2019 | 1987–2017 | 2000–2018 | 1984–2021 | 1994–2014 |
Group characteristics | Â | Â | Â | Â | Â |
Number of groupsd | 166 | 88 | 37 | 131 | 32 |
Numbers of patients per study group; median (IQR)h | 280 118–596 | 75 61–143 | 130 72–347 | 47 31–72 | 69 49–78 |
Mean length of stay < 7 days; (number of groups) | 27 | 14 | 12 | 14 | 2 |
Candidemia risk factors; (number of groups) | 11 | 0 | 0 | 21 | 14 |
Indicative intervention effect size (VAP / RT candida)i j | |||||
VAP Pseudomonas prevention effect (Additional file 1: Fig. S3) (odds ratio; 95% CI; n) | NA | 0.75; 0.61–0.91 (39) | 0.61; 0.38–0.97 (11) | 0.33; 0.26–0.42 (39) | NR |
RT candida prevention effect (Additional file 1: Fig. S5) (odds ratio; 95% CI; n) | NA | 0.62; 0.42–0.9 (19) | 0.37; 0.11–1.29 (8) | 0.54; 0.27–1.08 (15) | NR |
Indicative intervention effect sizei,k (Bacteremia/Candidemia) | |||||
Pseudomonas bacteremia prevention effect (Additional file 1: Fig. S4) (odds ratio; 95% CI; n) | NA | 7.46; 0.47–120 (1) | 1.0 0.67–1.5 (7) | 0.82; 0.52–1.29 (19) | NR |
Candidemia prevention effect (Additional file 1: Fig. S6) (odds ratio; 95% CI; n) | NA | 1.01; 0.06–16.1 (1) | 0.75 0.55–1.03 (7) | 0.48; 0.27–0.85 (17) | 0.43; 0.23–0.8 (16)l |